Extra-Cranial Bleeding and Other Symptoms due to Low Dose Aspirin and Low Intensity Oral Anticoagulation

Summary

Data from the early stages of the thrombosis prevention trial (TPT) have been used to establish and quantify the risk of extracranial bleeding due to low dose aspirin (75 mg) and low intensity oral anticoagulation with warfarin (international normalised ratio, INR, 1.5) singly or in combination, in men aged between 45 and 69 who are at high risk of ischaemic heart disease (IHD). The design of the trial is factorial, the four treatments being combined low dose aspirin and low intensity anticoagulation (WA), low intensity anticoagulation alone (W), low dose aspirin alone (A) and double placebo treatment (P). The trial is being carried out through the Medical Research Council’s General Practice Research Framework, with participating practices throughout the United Kingdom. Results are based on the first 3,667 men entered. The risk of major gastrointestinal bleeding due to active treatment is probably about 1 in 500 man-years of treatment, there currently being no difference between the three active regimes (WA, W, A). Intermediate and minor bleeding episodes occur more frequently with WA than with W or A on their own, the excess being mainly due to minor nose bleeds and bruises. In turn, both W and A on their own cause more such minor episodes than placebo treatment, P. There is no evidence that any of the three active regimes increases the risk of peptic ulceration, nor do they increase reports of indigestion. Aspirin increases reports of constipation and reduces reports of blurred vision. Minor bleeding occurs less frequently in smokers than in non-smokers but is not influenced by age. The antithrombotic regimes used are feasible and acceptable. So far, combined treatment and treatment with warfarin alone are not associated with more frequent serious hazards than low dose aspirin on its own, a regime that is increasingly used in clinical practice. The results provide a measure of reassurance for further trials of low intensity oral anticoagulation with warfarin alone or in combination with low dose aspirin.

• References

• 1 De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-901
• 2 Davies MJ. Thrombosis in acute myocardial infarction and sudden death. Thrombosis and Platelets in Myocardial Ischemia. F A Divis Company; Philadelphia, PA: 1987. 10 151-159
• 3 Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-1140
• 4 Antiplatelet Trialists’ Collaboration Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988 296. 320-331
• 5 Physicians’ Health Study Research Group Final report of the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989 321. 129-135
• 6 Peto R, Gray R, Collins R. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-316
• 7 RISC Group Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990 336. 827-830
• 8 International Anticoagulant Review Group Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. Lancet 1970 1. 203-209
• 9 Chalmers TC, Matta RJ, Smith H, Kunzler AM. Evidence favouring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977; 297: 1091-1096
• 10 Armitage P. Clinical trials in the secondary prevention of myocardial infarction and stroke. Thromb Haemostas 1980; 43: 90-94
• 11 Report of the Sixty Plus Reinfarction Study Research Group A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980 2. 989-994
• 12 Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-152
• 13 Meade TW, Mellows S, Brozivic M. et al Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
• 14 Meade TW, Miller GJ, Rosenberg RD. Characteristics associated with the risk factors for thrombosis and prethrombotic state. Thrombosis in Cardiovascular Disorders. W B Saunders Company; Philadelphia, PA: 1991
• 15 Miller GJ, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD. Haemostatic changes that constitute the hypercoagulable state. Lancet 1991; 338: 1079
• 16 Lowe GDO. Haemostatic changes and the hypercoagulable state. Lancet 1991; 338: 1526
• 17 Hull R, Hirsh J, Jay R. et al Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-1681
• 18 Francis CW, Marder VJ, McCollister EvartsC, Yaukoolbodi S. Two-step warfarin therapy. JAMA 1983; 249: 374-378
• 19 Saour JN, Sieck JO, Rahim Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-432
• 20 Powers PJ, Gent M, Jay RM. et al A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149: 771-774
• 21 Turpie AGG, Gunstensen J, Hirsh J. et al Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1: 1242-1245
• 22 Boston Area Anticoagulation Trial for Atrial Fibrillation The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990 323. 1505-1511
• 23 Altman R, Rouvier J, Gurfinkel E. et al Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427-431
• 24 Poller L, McKernan A, Thomson JM. et al Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987; 295: 1309-1312
• 25 Bern MM, Lokich JJ, Wallach SR. et al Very low doses of warfarin can prevent thrombosis in central venous catheters. Am Coll Physicians 1990; 112: 423-428
• 26 Fordyce MJF, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. Br Med J 1991; 303: 219-220
• 27 Altman R, Boulton F, Rouvier J. et al Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thoracic Cardiovasc Surg 1976; 72: 127-129
• 28 Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980; 99: 746-752
• 29 Chesebro JH, Fuster V, Elveback UR. et al Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537-1541
• 30 Miller A, Lees RS. Simultaneous therapy with antiplatelet and anticoagulant drugs in symptomatic cardiovascular disease. Stroke 1985; 16: 668-675
• 31 ISIS-2 Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988 2. 349-360
• 32 Meade TW, Wilkes HC, Stirling Y. et al Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Euro Heart J 1988; 9: 836-843
• 33 Meade TW. Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. Am J Cardiol 1990; 65: 7c-11c
• 34 Pocock SJ. Clinical Trials: A Practical Approach. John Wiley & Sons Ltd; New York: 1983
• 35 Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol 1980; 112: 467-470
• 36 Cohen M, Fuster V, Chesebro JH. Unstable angina: aspirin and anticoagulant use. Curr Opinion Cardiol 1989; 4: 510-512
• 37 Prichard PJ, Kitchingman GK, Walt RP. et al Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. Br Med J 1989; 298: 493-496
• 38 Aspirin Myocardial Infarction Study Research Group A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980 243. 661-669
• 39 UK-TIA Study Group United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988 296. 316-320
• 40 The Persantine-Aspirin Reinfarction Study Research Group Persantine and aspirin in coronary heart disease. Circulation 1980 62. 449-461
• 41 Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990; 265: 1711-1713
• 42 Boysen G, Sorensen PS, Juhler M. et al Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 1988; 19: 1211-1215
• 43 Petersen P, Boysen G, Godtfredsen J. et al Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989; 1: 175-179
• 44 The SALT collaborative group Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991 338. 1345-1349
• 45 The Dutch TIA trial study group A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991 325. 1261-1266
• 46 Gurewich V, Lipinski B, Hyde E. et al The effect of the fibrinogen concentration and the leukocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Haemostas 1976; 36: 605-614
• 47 Chooi CC, Gallus AS. Acute phase reaction, fibrinogen level and thrombus size. Thromb Res 1989; 53: 493-501
• 48 Naski MC, Shafer JA. A kinetic model for the α-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III. J Biol Chem 1991; 266: 13003-13010
• 49 Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875